FDA clears Medtronic’s Hugo robot for 3.5 million abdominal surgeries
Medtronic has gained FDA clearance to use its Hugo surgical robot in upper and lower abdominal procedures, addressing a market of 3.5 million annual operations.
Medtronic has received clearance from the U.S. Food and Drug Administration to use its Hugo robotic-assisted surgery system for general abdominal operations. The regulatory decision allows the modular platform to carry out common interventions across both the upper and lower abdomen.
Expanding into Abdominal Operations
The latest clearance covers upper abdominal procedures such as cholecystectomyCholecystectomyA surgical operation to remove the gallbladder. Open in glossary, Roux-en-Y gastric bypass, ventral hernia repair, and small bowel resection. It also includes lower abdominal operations, specifically appendectomies and inguinal hernia repairs. Medtronic estimates that these types of surgeries represent approximately 3.5 million procedures in the United States every year.
Hugo uses a cart-based, modular architecture that allows surgical teams to deploy only the robotic arms required for an individual case. Medtronic previously obtained FDA clearance for urological procedures in December 2025 after initiating its domestic rollout earlier that year. To secure the broader general surgery clearance, the company paired data from an American clinical trial with clinical evidence gathered abroad, where European regulators granted CE mark approval in 2022.
AI Integration and Future Clinical Trials
Beyond hardware deployment, Medtronic plans to integrate artificial intelligence across every stage of patient care. The company intends to apply machine learning to preoperative planning, live intraoperative guidanceGuidanceWhat a company says it expects to earn in the coming months. Open in glossary, and postoperative recovery tracking. In June, the firm received regulatory clearance for Touch Surgery Aide, an operating room computing system that deploys computer vision to analyze live video feeds during surgery.
The company expects the Hugo platform to exceed 50,000 total operations globally by the end of its current fiscal year. Looking ahead, Medtronic is conducting an investigational trial in the United States to assess Hugo for gynecological surgeries, including radical and total hysterectomies. The company also broadened its footprint through a $700 million investment in Cornerstone Robotics to distribute that firm’s Sentire surgical platform in certain international markets.
How does this story land?
One tap per reader.
Quick poll
Will robotic systems soon replace standard laparoscopic equipment in general surgery?
One tap. No sign-up.
Ask this story
Still have a question?
Answers use only what is in this story. They are written by AI and can be wrong.